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NEBIVOLOL INDUCED HYPERKALEMIA: 
CASE REPORT
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SUMMARY – In this article, we document a conclusive case of nebivolol-induced hyperkalemia 
for the fi rst time in the known medical literature. Hyperkalemia is associated with serious conditions 
such as cardiac arrhythmias and sudden cardiac death. Nebivolol was not known to cause hyperkale-
mia, and this event is not listed in its summary of product characteristics (SmPC). For older beta 
blockers, hyperkalemia is recognized as a rare adverse event linked to cytochrome P450 2D6 (CYP2D6) 
polymorphism and poor drug degradation. Our patient, a 47-year-old woman taking nebivolol for 
hypertension developed persistent hyperkalemia, with serum potassium levels up to 6.4 mmol/L. 
 After extensive diagnostic evaluation and exclusion of other known conditions leading to hyperkale-
mia, its cause remained occult. Since hyperkalemia coincided with increased doses of nebivolol, dose 
reduction and discontinuation were attempted, resulting in normalized serum potassium. Poor drug 
metabolism could not explain this adverse eff ect, since pharmacogenetic testing showed no relevant 
aberrations. In conclusion, hyperkalemia is a harmful adverse event with possible lethal outcome, and 
it may be caused by nebivolol. Th erefore, medical professionals have to be aware of this side eff ect and 
hyperkalemia should be listed as an adverse event in nebivolol SmPC.
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Introduction
Nebivolol is a third-generation beta blocking agent 
with high selectivity for beta-1 adrenergic receptors1,2, 
used in the treatment of hypertension, heart failure 
and cardiac arrhythmias1,3-6. It reverses left ventricular 
remodeling, increases stroke volume, preserves cardiac 
output and improves diastolic dysfunction5. Its antihy-
pertensive eff ect is due to reduced peripheral vascular 
resistance and vasodilatation resulting from facilitated 
release of nitric oxide1,7. Major adverse eff ects include 
headache, fatigue, dizziness, diarrhea, hyperlipopro-
teinemia, hyperuricemia and peripheral edema.
Hyperkalemia is not listed in nebivolol summary of 
product characteristics (SmPC)8,9. However, mild hy-
perkalemia is known to be caused primarily by nonse-
lective beta blockers, but there are also some case re-
ports of more cardioselective beta blocking agents 
such as atenolol and metoprolol causing hyperkale-
mia10-14. Although there is a report of nebivolol-related 
hyperkalemia to regulatory agencies (1 case in the 
open Food and Drug Administration database of ad-
verse events in February 2016), there are still concerns 
about its causality. Th e information on this website re-
lates to suspected side eff ects, i.e. medical events that 
were observed following the use of a medicine, but 
which were not necessarily related to or caused by the 
particular drug15.
Th ere is still no conclusive evidence for nebivolol-
induced hyperkalemia in medical literature because 
case reports are lacking. Th ere was a single assumption 
of nebivolol related hyperkalemia published in 2002, 
describing a case of an elderly patient with interfering 
comorbidities, but without defi nitive proof16.
Th e underlying mechanism of hyperkalemia relat-
ed to beta blockers usually considered is reduced cel-
lular potassium uptake due to decreased Na+/K+-
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ATPase pump activity12,17, suppressed catecholamine-
dependent renin release, and thereby diminished aldo-
sterone synthesis10,18. Like many other adverse eff ects 
of beta blockers, hyperkalemia was linked to poor drug 
degradation due to cytochrome P450 2D6 (CYP2D6) 
polymorphism and increased drug bioavailability. 
 Particularly for nebivolol, the bioavailability of orally 
taken drug is 12% on average in patients with exten-
sive metabolism, in comparison to 96% in poor me-
tabolizers. Peak concentration of nebivolol in plasma 
of persons with poor metabolism is up to 23 times 
higher than in those with extensive metabolism19-21, 
increasing the possibility of adverse events. However, it 
seems that nebivolol is metabolized through diff erent 
pathways in extensive and poor metabolizers, resulting 
in a higher concentration of active metabolites in ex-
tensive metabolizers, but without clinical signifi cance. 
Despite major diff erences in drug disposition, the clin-
ical response was similar between extensive and poor 
metabolizers, likely as a result of active hydroxylated 
metabolites produced in extensive metabolizers21.
Case Report
We present a case of a 47-year-old woman taking 
nebivolol for hypertension, who developed severe per-
sistent hyperkalemia. Her medical history included 
hemorrhagic stroke 22 years before, recurrent kidney 
stones, and chronic cystitis. Hypertension was diag-
nosed four years before and she began treatment with 
nebivolol 2.5 mg qd. Initially, blood pressure was well 
controlled. All relevant laboratory fi ndings including 
serum electrolytes were within the normal range. After 
one year, the dose of nebivolol was raised to 5 mg qd 
due to poorly controlled blood pressure. Within weeks, 
an increase in serum potassium up to 6.4 mmol/L (ref-
erence range: 3.9-5.1 mmol/L) was noticed, with still 
not well-controlled hypertension (145/85 mm Hg). 
Th e patient was advised to take a low potassium diet 
and treatment with indapamide 2.5 mg qd was started. 
After failing to correct potassium levels, furosemide 40 
mg biw was added, but hyperkalemia and non-con-
trolled hypertension persisted. At the time, she was 
complaining of chronic fatigue and lack of appetite, 
resulting in 2-kg weight loss over 2 months. Her phys-
ical examination showed discrete pretibial edema.
Her basic hematologic and metabolic panel re-
vealed a serum potassium level of 5.5 mmol/L, but 
other relevant blood fi ndings were normal. Urine spe-
cifi c gravity, creatinine clearance, and potassium excre-
tion in 24-h urine were within the reference range, 
while calcium and phosphate excretion was slightly 
reduced. Urinary albumin level and protein electro-
phoresis showed no abnormalities. Urine sediment 
analysis showed no relevant fi nding. 
Ultrasound revealed normal renal and suprarenal 
morphology.
Hormonal evaluation excluded endocrine causes of 
hyperkalemia, with serum aldosterone, urinary 24-h 
aldosterone, plasma cortisol, urinary 24-h cortisol, cor-
ticotropin, basal plasma renin, renin after stimulation 
with furosemide and thyrotropin levels within the ref-
erence ranges.
She was taking no other drugs and did not suff er 
from diseases and states leading to massive cell de-
struction such as rhabdomyolysis, tissue necrosis, or 
burns. Pseudohyperkalemia was ruled out by well con-
trolled venipuncture and repeated blood sampling.
Since the occurrence of hyperkalemia coincided 
with the nebivolol dose increase, dose reduction to 2.5 
mg nebivolol qd was attempted, resulting promptly in 
normalized serum potassium. Nebivolol was discon-
tinued and serum potassium level remained within the 
normal range.
After considering several therapeutic options, per-
indopril 2 mg qd and indapamide 0.625 mg qd were 
introduced. Blood pressure normalized at 135/80 mm 
Hg and peripheral pulse was 80 bpm. Fatigue and pre-
tibial edema disappeared.
Variations of potassium concentration and blood 
pressure due to diff erent antihypertensive drugs are 
shown in Table 1.
Although hyperkalemia is not listed in the nebivo-
lol SmPC, in this patient hyperkalemia was an adverse 
eff ect of nebivolol, as a sequence of the events revealed. 
Th is conclusion could be supported by using specifi c 
tools such as Naranjo Adverse Drug Reaction Proba-
bility Score and the World Health Organization Up-
psala Monitoring Centre Probability Scale22,23. Since 
hyperkalemia was serious and manifested with symp-
toms, additional pharmacogenetic testing focused on 
CYP2D6 polymorphism was performed. It showed 
the patient to be an extensive metabolizer of beta 
blocking agents, with both alleles of the wild type, so 
poor metabolism and abnormal pharmacokinetics 
could not explain the occurrence of hyperkalemia in 
this patient.
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Discussion and Conclusion
Hyperkalemia is a known side eff ect of several old-
er beta blockers including nonselective and some se-
lective members of the class. Th e occurrence of hyper-
kalemia with these drugs was thought to be linked to 
poor metabolism due to CYP2D6 polymorphism.
Th ere is still no conclusive report of hyperkalemia 
induced by nebivolol therapy in the literature up to 
now. Although hyperkalemia is not recognized as a 
side eff ect of nebivolol therapy, it seems that nebivolol 
is capable to cause signifi cant hyperkalemia.
In the patient described in this article, hyperkale-
mia was a side eff ect of nebivolol. Th is conclusion is 
based on the sequence of events, exclusion of other 
possible causes of hyperkalemia, and supported by 
laboratory fi ndings.
Causal relationship of drug related hyperkalemia 
has been confi rmed as defi nitive/certain according to 
Naranjo Adverse Drug Reaction Probability Score of 9 
and the World Health Organization Uppsala Moni-
toring Centre Probability Scale22,23.
Th e severity of hyperkalemia did not correlate with 
its antihypertensive eff ect, it occurred at a higher drug 
dose, and appeared to be reversible after drug discon-
tinuation. Because of the risks associated with hyper-
kalemia, re-challenge was not performed. Interestingly, 
additional pharmacogenetic testing did not explain the 
occurrence of this side eff ect, since the patient was 
found to be extensive metabolizer of beta blocking 
agents. In fact, if she were poor metabolizer due to 
CYP2D6 polymorphism, the potential accumulation 
of the drug would have surely resulted in a more pro-
found blood pressure reduction.
A reasonable genetic explanation for hyperkalemia 





and ADRB2) polymorphism, but data linking adverse 
eff ects of beta blockers to these genetic variants are 
still very rare and limited, not allowing any defi nite 
conclusion at this time24.
Finally and most importantly, hyperkalemia as a 
harmful adverse event must be listed as an adverse 
event in the nebivolol SmPC.
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Sažetak
HIPERKALIJEMIJA IZAZVANA NEBIVOLOLOM: PRIKAZ SLUČAJA
K. Altabas, V. Altabas i T. Gulin
U ovom članku je po prvi put u poznatoj medicinskoj literaturi dokumentiran slučaj hiperkalijemije izazvane nebivolo-
lom. Hiperkalijemija je povezana s ozbiljnim stanjima kao što su srčane aritmije i iznenadna srčana smrt. Za nebivolol dosad 
nije bilo poznato da može uzrokovati hiperkalijemiju pa ona nije navedena u sažetku opisa svojstava lijeka. Za starije beta 
blokatore hiperkalijemija je poznata kao rijetka nuspojava lijeka vezana uz polimorfi zam citokroma P450 2D6 (CYP2D6) i 
slabiju razgradnju lijeka. Nebivolol je uzimala i naša 47-godišnja bolesnica zbog hipertenzije, s posljedičnim razvojem refrak-
torne hiperkalijemije, s razinama serumskog kalija do 6,4 mmol/L. Nakon opsežne dijagnostičke evaluacije i isključenja 
drugih poznatih uvjeta koji dovode do hiperkalijemije njen uzrok nije razjašnjen. Pojava hiperkalijemije se podudarala s 
 povećanjem doze nebivolola, a smanjenje doze i prekid terapije doveli su do normalizacije serumskog kalija. Ova nuspojava 
nije se mogla objasniti usporenim metabolizmom lijeka budući da farmakogenetičko testiranje nije pokazalo relevantnih 
aberacija. U zaključku napominjemo da je hiperkalijemija štetan događaj s mogućim smrtnim ishodom koja može biti uzro-
kovana nebivololom. Stoga liječnici moraju biti svjesni ove nuspojave i hiperkalijemija treba biti navedena kao moguća nus-
pojava u sažetku opisa svojstava ovoga lijeka.
Ključne riječi: Nebivolol; Štetan događaj; Hiperkalijemija
